TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06371859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: XAI feedback on MCA/UA Doppler spectral curves and gate placement suggestions
Description: This study includes 1840 ultrasound images, split into UA and MCA flow and spectrum images, each duplicated for a total of 3680 images to compare explainable AI (XAI) feedback vs. no feedback. The investigators will provide matched sets of 40 images (one for the XAI group and one for the non-XAI group) to participants. Participants are matched based on their level of experience within each hospital (Resident physicians, obstetricians, and gynecologists with obstetric ultrasound experience).~All participants are instructed to place gates on the flow images of the umbilical artery and the middle cerebral artery and to assess the quality of the resulting flow curves. Specifically, for flow images, participants must identify the most appropriate gate placement. For spectral flow curves, they are to decide if the curves are of sufficient quality to guide medical management decisions.
Study: NCT05532514

Intervention type: OTHER
Intervention: MICRONUCLEI COUNT
Description: MICRONUCLEI COUNT IN PRECBCT and POSTCBCT EXPOSURE

Intervention type: OTHER
Intervention: MICRONUCLEI COUNT
Description: MICRONUCLEI COUNT IN PRECBCT and POSTCBCT EXPOSURE
Study: NCT05396872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant Surveys
Description: Online surveys administered post appointment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant Surveys
Description: Online surveys administered post appointment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Mobile application installed on mobile device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Mobile application installed on mobile device
Study: NCT05336851

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)
Study: NCT05033951

Intervention type: OTHER
Intervention: Standard care
Description: Both groups: standard care+ questionnaires

Intervention type: OTHER
Intervention: Standard care
Description: Both groups: standard care+ questionnaires
Study: NCT05897320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion
Study: NCT05305612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early anticoagulation
Description: Anticoagulation prior to transseptal puncture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: late anticoagulation
Description: Anticoagulation after transseptal puncture
Study: NCT06233227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride-Test product
Description: Dutasteride soft capsule 0.5 mg Test product Manufactured by: Phil Inter Pharma Co., Ltd., Vietnam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride-Reference product
Description: Dutasteride soft capsule 0.5 mg Reference product Manufactured by: DELPHARM POZNAN S.A., Poland
Study: NCT06533358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1002 Injection
Description: MT1002 is infused once only, once for 4h. MT1002 is for subjects with acute coronary syndrome undergoing PCI
Study: NCT06203782

Intervention type: PROCEDURE
Intervention: endoscopic stricturoplasty
Description: Experimental Group: In the experimental group, 51 patients underwent endoscopic stricturoplasty. A transparent cap was mounted on the front end of the endoscope, and a needle knife was inserted through the working channel of the endoscope. Under direct visualization, a radial incision was made at the site of the stricture, with an effort to preserve normal mucosal tissue as much as possible. The stricture was gradually incised until the endoscope could smoothly pass through.

Intervention type: PROCEDURE
Intervention: endoscopic balloon dilation
Description: Control Group: In the control group, 51 patients underwent endoscopic balloon dilation. The endoscope was advanced to the site of the stricture, and a dilation guidewire was inserted. After placing the balloon, it was progressively inflated with pressure, each inflation lasting 1-2 minutes, and this process was repeated 2-3 times until the endoscope and sheath could pass through the narrowed segment and enter the distal colon.
Study: NCT04615884

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese herbs formula: Shu Yu Wan
Description: Shu Yu Wan Formula is a combination of 23 natural chinese herbs.This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo
Study: NCT05718063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAP for Coaches - Complete Course
Description: The MAP for Coaches is an eLearning (web-based) knowledge translation training course aimed at providing youth sport coaches with the evidence-based education and motivation they need to reduce the risk of musculoskeletal injuries in young athletes. Course modules include a description of: (1) musculoskeletal injuries in youth sport; (2) the importance of injury prevention, and instructions on: (1) applying best practices for musculoskeletal athletic injury prevention, including neuromuscular training programs; (2) using behavioral strategies to successfully implement neuromuscular training warm-up programs in coaching sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Map for Coaches - Overview
Description: This is a summarized version of the MAP for Coaches. It comprises a 2-page sport-specific injury prevention e-book (reading) containing an overview of the MAP for Coaches training and an infographic summary.
Study: NCT06086366

Intervention type: OTHER
Intervention: [11C]DTBZ PET scan
Description: One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)

Intervention type: OTHER
Intervention: [11C]DTBZ PET scan
Description: One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)

Intervention type: OTHER
Intervention: [18F]SDM8 PET scan
Description: One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)

Intervention type: OTHER
Intervention: [18F]SDM8 PET scan
Description: One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)

Intervention type: OTHER
Intervention: MRI scan
Description: One MRI scan

Intervention type: OTHER
Intervention: MRI scan
Description: One MRI scan
Study: NCT06515145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Volume Therapeutic Plasma Exchange
Description: Experimental- High Volume Therapeutic Plasma Exchange at (8 - 9 litres of plasma would be exchanged in each patient over 6 - 8 hours)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard volume therapeutic plasma exchange
Description: Active Comparator - The standard volume strategy would be performed centrifugation technique with Plasma volume varying from 1.5 - 2.5 times the plasma - volume along with Standard Medical Treatment.
Study: NCT05871684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTK inhibitor
Description: Intervention were given during bridging therapy and maintanance treament of CAR-T cell therpay.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intervention were given during maintanance treament of CAR-T cell therpay.
Study: NCT06330012

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GeoMx data analysis with clinical outcome
Description: 1. List of HER2 positive breast cancer~   * Stage IV disease~  * Treated with T-Dxd~  * Available FFPE samples~2. Prepare tissue for digital spatial proteomics~   * FFPE/H\&E slide~  * Region of Interest(ROI) check~  * Make a Tissue microarray~  * Prepare special slide for GeoMx~3. GeoMx data analysis with clinical outcome
Study: NCT05191940

Intervention type: RADIATION
Group type: OTHER
Intervention: Particle-therapy using protons or carbon ions
Description: According to the radiation plan (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling
Description: Evaluation before treatment-start, after treatment and follow-up period.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic resonance imaging
Description: For treatment planning as well as for follow-up radiological tumor assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Computertomography
Description: For treatment planning as well as for follow-up radiological tumor assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)
Description: For treatment planning as well as for follow-up radiological tumor assessment.
Study: NCT06540885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron (Group P)
Description: Group P will be receiving palonosetron 1.5mcg/kg before the commencement of general anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron (Group G)
Description: Group G participants will receive IV Granisetron 1mg at the start of wound closure
Study: NCT06107114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400mg/m2 (The first week), 250mg/m2(Follow-up weekly) The drug was administered every week (QW). The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab 240 mg, The drug was administered every week (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
Study: NCT06057194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir 240 mg Oral Tablet
Description: Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation.
Study: NCT06107114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
Study: NCT04630184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure intervention in virtual reality
Description: 6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) with cognitive restructuring and VR exposure supervised by psychologists
Study: NCT05965804

Intervention type: DIAGNOSTIC_TEST
Intervention: McMurray knee examination test
Description: The McMurray test will be performed in different knee flexion and rotation angles.
Study: NCT04630184

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants will have to go twice a week, for 12 weeks to carry out 2 individual endurance training sessions of 45 minutes (moderate to vigorous intensity), supervised by a kinesiologist. Participants will also have to complete a 3rd 60-minute endurance session at home (or two 30-minute sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will have to go twice a week, for 12 weeks to carry out 2 individual endurance training sessions of 45 minutes (moderate to vigorous intensity), supervised by a kinesiologist. Participants will also have to complete a 3rd 60-minute endurance session at home (or two 30-minute sessions).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) Discussion around social physical anxiety, stress management (relaxation and breathing) supervised by psychologists
Study: NCT05841992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al18F-PSMA-617
Description: Intravenous injection of one dosage of 0.1mCi/kg Al18F-PSMA-617. Tracer doses of Al18F-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-617
Description: Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
Study: NCT04701359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TiN-alloy based total knee arthroplasty
Description: TiN-alloy based TKA implanted for knee osteoarthritis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoCr-coating based total knee arthroplasty
Description: CoCr-coating based TKA implanted for knee osteoarthritis.
Study: NCT06003140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celsi Warmer
Description: A trained study clinician will attach the Celsi Warmer temperature sensor to the abdomen and secure it with the abdominal belt according to the device's instruction manual (such that the temperature sensor is positioned using a vertical line from the mid-clavicular line and just below the ribs). The time of sensor placement will be recorded.
Study: NCT06488508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoveEarly
Description: The intervention has two levels: the kindergarten level and the child level.~1. Staff will receive approximately 60 hours of professional development, including 6 full-day physical seminars, 2 full-day kindergarten visits, 6 written tasks with follow-up webinars and an online resource. The focus will be how to promote movement, play and exploration among children aged 1-6 years.~2. Staff is supposed to promote children's movement, play and exploration through 7 pedagogical principles: 1. Value, understand and promote movement, 2. Value, understand and promote play, 3. Value, understand and promote exploration, 4. Create rich physical environments, 5. Create opportunities for meaningful participation, 6. Create good balance between challenge and support, and 7. Create good dialogue through action and words.
Study: NCT04714749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous treatment
Description: Treatment of great saphenous vein (its tributaries and possible incompetent perforators feeding the ulcer) by endovascular cyanoacrylate glue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue
Description: Treatment of great saphenous vein (its tributaries and possible incompetent perforators feeding the ulcer) by endovascular cyanoacrylate glue
Study: NCT06065683

Intervention type: PROCEDURE
Intervention: surgery
Description: Surgical procedures performed in the study period

Intervention type: PROCEDURE
Intervention: surgery
Description: Surgical procedures performed in the study period

Intervention type: PROCEDURE
Intervention: surgery
Description: Surgical procedures performed in the study period

Intervention type: PROCEDURE
Intervention: surgery
Description: Surgical procedures performed in the study period

Intervention type: PROCEDURE
Intervention: surgery
Description: Surgical procedures performed in the study period
Study: NCT05777421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy for Knee Osteoarthriths
Description: Participants of Group A will receive the conventional physical therapy for Knee Osteoarthistis for a duration of 6 weeks atleast 2 times a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Based Therapeutic Exercise regimes
Description: * Participants of Group B will receive Virtual Reality Based therapeutic exercises on the Xbox. The difficulty level of the games will progess each week. The duration of training will also also progress at treatment week progresses.~* Frequency: 2-3 times a week for 6 weeks. Minimum 12 sessions in total.
Study: NCT06502886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined protocol of retention (bonded lingual retainer and vacuum formed retainers)
Description: Combined bonded retainer and vacuum formed retainer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bonded lingual retainer
Description: Bonded retainer
Study: NCT05253287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
Study: NCT06143397

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Behavioral treatment
Description: It includes techniques and skills to prevent incontinence and restrain the urge to urinate. It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques. Additionally, advice on proper voiding position and an exercise protocol will be given. The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions. Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds. They will be told to do it twice a day, morning and evening. Participants will perform the behavioral training protocol at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Description: It includes techniques and skills to prevent incontinence and restrain the urge to urinate. It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques. Additionally, advice on proper voiding position and an exercise protocol will be given. The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions. Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds. They will be told to do it twice a day, morning and evening. Participants will perform the behavioral training protocol at home.
Study: NCT05507138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKL-T01
Description: AKL-T01 is an iPad-based video game designed to improve executive dysfunction and depression symptoms by targeting executive skills (multitasking) and ECN abnormalities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Strategy Training
Description: Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Metacognitive Strategy Training
Description: Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties